Diabetes drugs GLP-1RA and SGLT2i lower dementia risk in older adults, study finds

Hearing loss in older adults linked to nearly one-third of dementia cases

A multi‑institution research team including Columbia, Vanderbilt, Johns Hopkins and others, report that nearly one in three new dementia cases in older adults is associated with hearing loss, based on statistical modeling of population data.

Diabetes drugs GLP-1RA and SGLT2i lower dementia risk in older adults, study finds

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of glucose-lowering drugs used in type 2 diabetes, were associated with a significantly reduced risk of Alzheimer’s disease and related dementias (ADRD). These findings suggest potential neuroprotective benefits and highlight drug repurposing as a promising strategy for ADRD prevention.

GLP-1 Drugs Show Potential as Treatment for Bardet-Biedl Syndrome

Treatment with GLP-1 receptor agonists—medications currently approved for type 2 diabetes and obesity—may offer a new therapeutic option for patients with the rare genetic disorder Bardet-Biedl Syndrome (BBS). The study, published in the Journal of Clinical Investigation, which used an engineered mouse model that mirrors many features of human BBS, found that GLP-1 therapies significantly improved metabolic function, reduced food intake, and hel…